Capital deployed:
£1m SEIS & EIS qualifying
Use of funds:
- Establish team & facilities
- Further, develop lead assets
- Progress pre-clinical programmes
Capital deployed:
£1m SEIS & EIS qualifying
Use of funds:
- Establish team & facilities
- Further, develop lead assets
- Progress pre-clinical programmes
Founded in 2022 as a spin out from the University of Dundee, Glen Clova Scientific is developing a new generation of active biologic drugs for chronic inflammatory and autoimmune disorders. The initial seed funding round of £2.5m in April 2024 was supplemented with a further £1.4m in Q1 2025 enabling the Company to advance the preclinical development of its lead assets for the treatment of dermatological conditions.
DSW Ventures participated alongside Norcliffe Capital, TriCapital Angels and Scottish Enterprise in an initial combined SEIS and EIS investment and follow on EIS investment.